Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
在ELEVATE-TN研究的6年随访结果中,阿卡替尼联合奥妥珠单抗治疗与化疗免疫疗法相比,可改善初治慢性淋巴细胞白血病患者的生存期。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024024476
Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Patel, Krish; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Hughes, Marie; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Follows, George; Walker, Patricia; Ghia, Paolo; Janssens, Ann; Byrd, John C; Ferrant, Emmanuelle; Ferrajoli, Alessandra; Wierda, William G; Wachira, Catherine Wangui; Suterwala, Batul T; Miranda, Paulo; Munugalavadla, Veerendra; Wun, Chuan-Chuan; Woyach, Jennifer A